NovoCure (NVCR) Cash from Operations (2014 - 2026)

NovoCure (NVCR) has reported Cash from Operations for 13 consecutive years, with 8132000.0 the latest figure, recorded in Q2 2026.

• Quarterly Cash from Operations rose 151.03% year-over-year to 8132000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 2815000.0 (up 93.7% YoY) and the FY2025 annual result came in at 49031000.0, down 85.94% from the prior year.
• Cash from Operations climbed to 8132000.0 in Q2 2026 per NVCR's latest filing, from 13517000.0 in the prior quarter.
• Over the last five years, Cash from Operations for NVCR reached as high as 22420000.0 in Q3 2022 and fell as low as 35665000.0 in Q1 2025.
• A 5-year average of 6851833.33 and a median of 8612000.0 in 2022 frame the typical range for Cash from Operations.
• Annual changes were most pronounced in 2024 — Cash from Operations jumped 153.72% — and 2025, when it sank 826.51%.
• Year by year, Cash from Operations stood at 3707000.0 in 2022, then slumped by 292.72% to 14558000.0 in 2023, then jumped by 76.29% to 3451000.0 in 2024, then sank by 421.7% to 18004000.0 in 2025, then soared by 145.17% to 8132000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 8132000.0, 13517000.0, and 18004000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.